Bone Biologics (BBLGW) Common Equity (2016 - 2017)
Bone Biologics (BBLGW) has disclosed Common Equity for 2 consecutive years, with -$10.2 million as the latest value for Q3 2017.
- Quarterly Common Equity fell 46.24% to -$10.2 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was -$10.2 million through Sep 2017, down 46.24% year-over-year, with the annual reading at -$8.4 million for FY2016, N/A changed from the prior year.
- Common Equity for Q3 2017 was -$10.2 million at Bone Biologics, down from -$9.7 million in the prior quarter.
- The five-year high for Common Equity was -$3.2 million in Q1 2016, with the low at -$10.2 million in Q3 2017.